Boston Scientific Corporation Dividend History (BSX)
Boston Scientific Corporation does not pay dividends currently 😔
They might in the future, check back soon!
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in the medical device industry, dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. It operates in segments like interventional cardiology, rhythm management, endoscopy, urology and pelvic health, neuromodulation, and more. As of the latest updates, its CEO is Michael F. Mahoney, who has been leading the company since 2012. Under his leadership, Boston Scientific has continued to expand its portfolio with cutting-edge technology and strategic acquisitions. The company generated revenues of approximately $11.9 billion in 2022, reflecting its robust market presence and continuous growth. Boston Scientific is known for its commitment to research and development, helping to drive advancements in minimally invasive medical procedures that enhance patient outcomes and reduce recovery times.
The endoprosthesis market is expected to grow significantly due to the increasing demand for joint replacements driven by an aging population and the rising prevalence of chronic degenerative diseases. Advancements in prosthetic materials and surgical techniques are improving patient outcomes, while increased healthcare access and awareness are further driving market growth.
GlobeNewswire Inc. · Published on Mon Dec 02 2024The artificial organs market is expected to grow at a CAGR of 7.68% from 2024 to 2031, driven by the increasing demand for organ transplants and advancements in medical technologies. The mechanical artificial organs segment is expected to dominate the market due to their reliability, low risk of failure, and affordability.
GlobeNewswire Inc. · Published on Mon Nov 25 2024The global urology devices market is expected to reach a valuation of $61.62 billion by 2031, driven by the increasing prevalence of urological disorders, advancements in minimally invasive surgeries, and the growing geriatric population.
Benzinga · Published on Wed Nov 13 2024